Psilocybin Study Shows Early Promise for Parkinson’s Patients
A new clinical trial has found that psilocybin, the active compound in psychedelic mushrooms, may help ease both motor and mood symptoms in people living with Parkinson’s disease. The findings, presented at the 2024 American Academy of Neurology meeting, suggest that the psychedelic compound could offer a new pathway for symptom management in this hard-to-treat condition.
New: Interested in Being Part of a Psychedelics-Focused Clinical Trial? Sign Up Here
Here is a breakdown of the key findings:
| Key Takeaway | Details |
|---|---|
| Study Size | 12 patients with Parkinson’s disease |
| Treatment | Single 25 mg oral dose of psilocybin |
| Mood Improvements | 83% showed meaningful reductions in anxiety or depression |
| Motor Improvements | 75% had improved motor scores, particularly tremor and bradykinesia |
| Onset of Effects | Most patients noticed effects within 2 days |
| Duration of Benefits | Effects lasted at least 2 weeks for many participants |
| Adverse Effects | Mild and short lived, including nausea and headache |
| Next Steps | Larger trials needed to confirm safety and efficacy |
Looking for treatment? Find ketamine clinics closest to you as well as other psychedelic therapies in your area.
A Fast Response with Minimal Side Effects
Participants received a single 25 mg capsule of psilocybin in a clinical setting with professional monitoring. Most reported noticeable improvements in anxiety and depression within 48 hours. Many also experienced a reduction in tremors and other movement-related symptoms that are common in Parkinson’s disease. Notably, these benefits were observed without serious side effects. Some participants experienced mild nausea or a brief headache, but the symptoms resolved quickly.
The trial, led by researchers from the Pacific Neuroscience Institute, focused on individuals who were already taking standard Parkinson’s medications. Psilocybin was used as an adjunct, not a replacement. While the results are preliminary, they open the door to a potential new class of supportive therapies.
A Shift in How We Understand Treatment
Parkinson’s disease is typically associated with motor dysfunction, but mood disorders such as anxiety and depression also affect quality of life. Traditional medications do little to address both sets of symptoms at once. Psilocybin’s ability to target both areas could shift how clinicians think about treatment strategies.
Still, the study’s small size limits broad conclusions. Larger, placebo-controlled studies will be essential before psilocybin can be considered a standard treatment option.
Yet for those living with a condition that gradually takes away mobility and independence, the possibility of an effective new tool brings hope. As research into psychedelic therapies expands, psilocybin continues to emerge as one of the most closely watched compounds in the neuroscience field.
